Champions Oncology, Inc. - CSBR STOCK NEWS

Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its second quarter financial results announcement for Wednesday, December 11, 2024, after market close. The company will host a conference call at 4:30 P.M. EST to discuss the results for the quarter ended October 31, 2024. Investors can join via phone or access the replay through the company's website within 72 hours.

Champions Oncology (Nasdaq: CSBR) has announced a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing. This collaboration grants Champions Oncology exclusive rights to distribute and commercialize Weill Cornell Medicine's hematological patient-derived xenograft (PDX) models.

The PDX models were developed by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine. Champions Oncology will serve as a repository to distribute these models to academic institutions worldwide, enhancing its position in the heme-oncology field.

This strategic partnership aligns with Champions Oncology's commitment to providing advanced preclinical oncology solutions and strengthens its portfolio in hematological research. The collaboration is expected to facilitate rapid and scalable access to these unique PDXs for both biopharma partners and academic institutions.

Champions Oncology (NASDAQ:CSBR) reported strong financial results for Q1 FY2025. Revenue increased 12% to $14.1 million, with improved margin of 50%. The company achieved adjusted EBITDA of $2.0 million and net income of $1.3 million. Cost reductions and operational efficiencies contributed to profitability. Total costs decreased by $2.4 million (15.8%) compared to Q1 FY2024. The company ended the quarter with $2.9 million in cash and no debt. CEO Ronnie Morris expressed cautious optimism about weathering the business downturn and positioning for future growth.

Champions Oncology (CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has announced it will release its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results at 4:30 P.M. EDT on the same day. Investors can join the call using the provided domestic and international dial-in numbers and access code. A replay of the call will be available via phone or through the company's website within 72 hours of the call.

Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024. Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000. However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million. The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending patterns. Cost-cutting measures and operational efficiencies were implemented, showing positive results in Q4. Champions is optimistic about returning to consistent profitability in fiscal 2025. The company ended Q4 with a cash position of $2.6 million and no debt.

Champions Oncology (NASDAQ: CSBR), a global provider of preclinical and clinical research services, will announce its financial and operational results for Q4 and the fiscal year ended April 30, 2024, on July 18, 2024, after market close.

The company will hold a conference call at 4:30 P.M. EST (1:30 P.M. PST) to discuss the results. Participants can join the call domestically by dialing 888-506-0062 or internationally at 973-528-0011 using access code 135832. A replay will be available within 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode: 50895, or through the investor section of the company's website.

Champions Oncology (CSBR) announced a strategic collaboration with Medicines Discovery Catapult (MDC) to boost the development of radiopharmaceutical therapeutics. This partnership leverages Champions' patient-derived models and pharmacology solutions with MDC's radiochemistry and multi-modal imaging expertise. The collaboration aims to advance radionuclide therapies, offering new hope for cancer patients. This synergy addresses the need for combined specialized expertise and clinically relevant models in radioligand therapies, positioning both organizations to drive significant advancements in the field.

Champions Oncology, Inc. (NASDAQ:CSBR) reports third quarter financial results with a revenue decline of 6% to $12.0 million. The company aims to navigate through economic challenges in the biotech sector and is actively engaging with investors to raise capital for its subsidiary, Corellia, AI. Despite lower revenue growth, Champions is strategically reducing costs to improve short-term results. The company's loss from operations for the third quarter of fiscal 2024 was $2.6 million, with an adjusted EBITDA loss of $1.7 million. Total revenue for the first nine months of fiscal 2024 decreased by 11.4% to $36.2 million compared to the same period last year. Champions ended the quarter with approximately $4.5 million in cash and cash equivalents, with no debt.

Champions Oncology (CSBR) receives CAP accreditation for its US-based laboratory, further solidifying its reputation for excellence in histology and immunohistochemistry services. The company also attains ISO-9001:2015 and ATS certifications at its European Research Laboratories in Italy, showcasing its commitment to quality. CEO Ronnie Morris emphasizes the importance of these achievements in maintaining high scientific standards and contributing to partners' therapeutic studies.